Alzamend Neuro, Inc. (ALZN) Revenue, Earnings & Financial Statements
$1.13NCM: ALZNMarket Cap $5.45M
Data as of Nov 17, 2026 close · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)
Alzamend Neuro, Inc. most recently reported annual revenue of $0, a net loss of $9.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Alzamend Neuro, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $9.0M.
Income Statement — 10 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$2.0M
$1.0M
$5.0M
$4.0M
$5.0M
$12.0M
$15.0M
$10.0M
$4.0M
$9.0M
Operating Profit
−$2.0M
−$1.0M
−$5.0M
−$4.0M
−$5.0M
−$12.0M
−$15.0M
−$10.0M
−$4.0M
−$9.0M
Other Income
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$2.0M
$1.0M
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$2.0M
−$1.0M
−$5.0M
−$4.0M
−$5.0M
−$12.0M
−$15.0M
−$10.0M
−$5.0M
−$9.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$2.0M
−$1.0M
−$5.0M
−$4.0M
−$5.0M
−$12.0M
−$15.0M
−$10.0M
−$5.0M
−$9.0M
EPS
−$73.59
−$27.71
−$111.56
−$83.56
−$93.78
−$187.31
−$205.97
−$132.33
−$11.32
−$2.63
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$3.0M
$3.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$3.0M
$1.0M
$2.0M
$3.0M
$3.0M
Operating Profit
−$3.0M
−$3.0M
−$1.0M
−$1.0M
−$1.0M
−$1.0M
−$1.0M
−$3.0M
−$1.0M
−$2.0M
−$3.0M
−$3.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$3.0M
−$3.0M
−$1.0M
−$1.0M
−$1.0M
−$1.0M
−$1.0M
−$3.0M
−$1.0M
−$2.0M
−$3.0M
−$3.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$3.0M
−$3.0M
−$1.0M
−$1.0M
−$1.0M
−$1.0M
−$1.0M
−$3.0M
−$1.0M
−$2.0M
−$3.0M
−$3.0M
EPS
−$39.85
−$33.97
−$11.14
−$11.42
−$3.61
−$1.70
−$2.43
−$1.28
−$0.30
−$0.58
−$0.74
−$0.68
Over the 10 years reported for Alzamend Neuro, Inc., borrowings decreased from $1.0M in 2017 to $0 in 2026, cash stood at $1.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.00 times.
Balance Sheet — 10 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
$0
$2.0M
$2.0M
$2.0M
$3.0M
$15.0M
$6.0M
$1.0M
$5.0M
$2.0M
Current Assets
$0
$2.0M
$2.0M
$2.0M
$3.0M
$14.0M
$6.0M
$0
$4.0M
$2.0M
Cash
$0
$1.0M
$0
$0
$2.0M
$14.0M
$5.0M
$0
$4.0M
$1.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$1.0M
$0
$1.0M
$1.0M
$1.0M
$1.0M
$3.0M
$3.0M
$1.0M
$1.0M
Current Liabilities
$1.0M
$0
$1.0M
$1.0M
$1.0M
$1.0M
$3.0M
$3.0M
$1.0M
$1.0M
Borrowings
$1.0M
$0
$0
$0
$0
$0
$0
$0
$0
$0
Other Liabilities
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
$3.0M
$3.0M
$1.0M
$1.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
−$1.0M
$2.0M
$0
$1.0M
$2.0M
$13.0M
$3.0M
−$3.0M
$4.0M
$1.0M
For Alzamend Neuro, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $8.0M; free cash flow was positive in 0 of 10 years.
Cash Flow Statement — 10 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Operating Cash Flow
−$1.0M
−$2.0M
−$1.0M
−$2.0M
−$3.0M
−$7.0M
−$9.0M
−$8.0M
−$7.0M
−$8.0M
Investing Cash Flow
$0
$0
$0
$0
$0
$0
$0
$0
−$1.0M
$0
Financing Cash Flow
$1.0M
$0
$0
$2.0M
$2.0M
$0
$0
$0
$0
$0
Net Cash Flow
$0
$1.0M
−$1.0M
$0
$2.0M
$12.0M
−$9.0M
−$5.0M
$4.0M
−$3.0M
Free Cash Flow
−$1.0M
−$2.0M
−$1.0M
−$2.0M
−$3.0M
−$7.0M
−$9.0M
−$8.0M
−$7.0M
−$8.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.00
EV / EBITDA
0.06
FCF Yield
-97.13%
Quick Ratio
3.01
Interest Coverage
818.59
Return 1Y
-46.78%
Return 3Y
-99.02%
Return 5Y
-99.96%
Alzamend Neuro, Inc. (ALZN) financials — frequently asked questions
What is Alzamend Neuro, Inc.'s annual revenue?
Alzamend Neuro, Inc. (ALZN) reported annual revenue of $0 in its most recent fiscal year.
What is Alzamend Neuro, Inc.'s net profit?
Alzamend Neuro, Inc. (ALZN) reported a net loss of $9.0M in its most recent fiscal year.
What is ALZN EV/EBITDA?
Alzamend Neuro, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.06.
Revenue and earnings of other Biotechnology stocks